Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38179267

about

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future Adverse Effects of GLP-1 Receptor Agonists The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.Exenatide: pharmacokinetics, clinical use, and future directions.Novel antidiabetic nutrients identified by in vivo screening for gastric secretion and emptying regulation in rats.Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.

P2860

Q26752699-1B1CC3EB-8307-4D90-B896-DE931DF72F5E Q26801346-A7BA78F1-C005-456E-BC5F-794EF9A7BBCA Q28078225-E9981F58-9273-42AF-AB42-19A867658231 Q28543699-2D38FC79-7AC6-4D55-95CE-059E00578354 Q36307536-28067FC5-4F4D-41EE-A62E-5440187395BD Q38261573-625050F1-4F1B-40D3-9950-059A57B34BC3 Q38526870-D64FD36A-B34E-4739-9CD5-C4777FFF1C9F Q38749391-9D035D05-4283-4B7C-AA88-6FE027E107B1 Q38770746-72D949DF-20EC-4753-93EB-7ADF59763E32 Q43917600-85A95287-942A-44D1-9B0A-2F6DB35523B8 Q49971015-1FC01D43-6DEA-457A-BBCE-9D434CAF3507 Q51249870-91361C07-66B1-4818-9006-429AEDCECA01 Q51282489-5DF527FD-6645-409B-B9CA-B69F81FBDCAD

P2860

Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38179267

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Exenatide twice daily: a revie ...... with type 2 diabetes mellitus.

@en

type

label

Exenatide twice daily: a revie ...... with type 2 diabetes mellitus.

@en

prefLabel

Exenatide twice daily: a revie ...... with type 2 diabetes mellitus.

@en

P1433

Q38179267-8DFF6F3C-9DC5-4F91-B1A0-801C7949ABAC

P1476

Q38179267-71B738AF-3850-4893-9700-74D59FEB843C

P2093

Q38179267-11219264-5681-46D7-A797-32DC5ACB767A

P2860

Q38179267-0324CDAC-09FB-4699-A71E-8B5E1ECB1EAB

Q38179267-05F41C25-6779-4543-8F59-7D1289935A3A

Q38179267-098EDAAD-3FC4-4095-BA73-ABCBFA6AED88

Q38179267-0ACAF173-6A36-4941-89ED-DCD845ABA360

Q38179267-0BBFC910-5EBD-4D2F-BCDF-CC909EA8F32B

Q38179267-11BB663E-6A9D-42A4-8610-0BDE6D751DEB

Q38179267-11E7ADE9-164F-4F00-8E6B-3420AC9ADC1A

Q38179267-1466F227-C6B8-4450-920B-B1D6ACF900BF

Q38179267-16F7966C-B86A-498C-8B76-64EAF8BF661F

Q38179267-16F92354-FB62-4D0E-B862-64DD05722F71

P2888

Q38179267-0C172846-F12C-456E-9BE6-84F84C040518

P304

Q38179267-304BCE30-DD24-4E29-83F5-1220E58E79AC

P31

Q38179267-8765EE4E-98EB-4636-BE62-F6457DAF6BFC

P356

Q38179267-CAE5A860-F2B0-41B6-ABBA-4D009F6C04E7

P433

Q38179267-6EA9DC8E-F3E1-4FC3-8165-A3B4F9E2AFE0

P478

Q38179267-59B7BDA3-0683-4E46-AA19-A27A9B916CB3

P577

Q38179267-E5810351-7186-45CC-8FC1-B149BE2531EB

P6179

Q38179267-88B724FC-82F2-4A77-B558-6BA4B87EE711

P698

Q38179267-1B9859A9-C19E-453D-9CE6-B85FBE34AC95

P921

Q38179267-DB816E15-42AE-4ACA-A7DE-003C38D0AF36

P356

S40265-013-0172-6

P1433

P1476

Exenatide twice daily: a revie ...... with type 2 diabetes mellitus.

@en

P2093

Paul L McCormack

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Do incretin-based therapies cause acute pancreatitis?

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

P2888

s40265-013-0172-6

P304

325-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0172-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014138564

http://www.w3.org/2001/XMLSchema#string

P698

24435322

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes